Impact on postoperative bleeding and cost of recombinant activated factor VII in patients undergoing heart transplantation

Annals of Cardiac Anaesthesia

Volumn 19, Issue 3, 2016, Pages 418-424

  Hollis, Allison ^a   Lowery, Ashleigh ^a   Pajoumand, Mehrnaz ^a   Pham, Si ^a   Slejko, Julia ^a   Tanaka, Kenichi ^a   Mazzeffi, Michael ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Bleeding; Heart transplantation; Recombinant activated factor VII; Transfusion

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CHEST TUBE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG COST; DRUG USE; ERYTHROCYTE TRANSFUSION; FEMALE; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPERATIVE BLOOD LOSS; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; REOPERATION; STERNOTOMY; THROMBOEMBOLISM; ECONOMICS; HEART SURGERY; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; CARDIAC SURGICAL PROCEDURES; COAGULANTS; COHORT STUDIES; FACTOR VIIA; FEMALE; HEART TRANSPLANTATION; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84978811158     PISSN: 09719784     EISSN: 09745181     Source Type: Journal    
DOI: 10.4103/0971-9784.185523     Document Type: Article

References (18)

1. Marietta M, Facchini L, Pedrazzi P, Busani S, Torelli G. Pathophysiology of bleeding in surgery. Transplant Proc 2006;38:812-4.
2. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-11.
3. Hein OV, Birnbaum J, Wernecke KD, Konertz W, Jain U, Spies C. Three-year survival after four major post-cardiac operative complications. Crit Care Med 2006;34:2729-37.
4. Herbertson M. Recombinant activated factor VII in cardiac surgery. Blood Coagul Fibrinolysis 2004;15 Suppl 1:S31-2.
5. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005;95:596-602.
6. Levy JH. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001;72:S1814-20.
7. Grounds M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: A review. Blood Rev 2003;17 Suppl 1:S11-21.
8. DiDomenico RJ, Massad MG, Kpodonu J, Navarro RA, Geha AS. Use of recombinant activated factor VII for bleeding following operations requiring cardiopulmonary bypass. Chest 2005;127:1828-35.
9. Gandhi MJ, Pierce RA, Zhang L, Moon MR, Despotis GJ, Moazami N. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg 2007;2:32.
10. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M, et al. Safety and efficacy of recombinant activated factor VII: A randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7.
11. Romagnoli S, Bevilacqua S, Gelsomino S, Pradella S, Ghilli L, Rostagno C, et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 2006;102:1320-6.
12. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
13. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005;352:777-85.
14. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011;2: CD005011.
15. Ekert H, Brizard C, Eyers R, Cochrane A, Henning R. Elective administration in infants of low-dose recombinant activated factor VII (rFVIIa) in cardiopulmonary bypass surgery for congenital heart disease does not shorten time to chest closure or reduce blood loss and need for transfusions: A randomized, double-blind, parallel group, placebo-controlled study of rFVIIa and standard haemostatic replacement therapy versus standard haemostatic replacement therapy. Blood Coagul Fibrinolysis 2006;17:389-95.
16. Essam M. Prophylactic administration of recombinant activated factor VII in coronary revascularization surgery. Internet J Anesth 2007;13:10.
17. Ma B, Wang Z, Zhang BR, Li J. Effect of recombinant activated factor VIIa on early recovery of patient undergoing cardiac valve replacement under cardiopulmonary bypass; a randomized double-blind placebo-controlled trial. Acad J Second Mil Med Univ 2006;27:1110-3.
18. Goldstein JN, Refaai MA, Milling TJ Jr., Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid Vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015;385:2077-87.